Bank of New York Mellon
KYTX icon

Bank of New York Mellon’s Kyverna Therapeutics KYTX Stock Holding History

Bank of New York Mellon’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$894K Buy
+100,281
New +$890K ﹤0.01% 3433
2025
Q2 		– Sell
-48,784
Closed -$94.2K – 4289
2025
Q1 		$94.2K Buy
48,784
+8,851
+22% +$26.2K ﹤0.01% 4007
2024
Q4 		$149K Sell
39,933
-3,333
-8% -$16K ﹤0.01% 3999
2024
Q3 		$212K Sell
43,266
-12,524
-22% -$96.6K ﹤0.01% 3890
2024
Q2 		$418K Buy
+55,790
New +$852K ﹤0.01% 3675

Other funds holding KYTX

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Bank of New York Mellon's KYTX Position: Q2 2026 in Review

Bank of New York Mellon opened a new position in Kyverna Therapeutics (KYTX) in Q2 2026: 100,281 shares worth $894K. The stake represents ﹤0.01% of the portfolio and ranks #3433 among its holdings. This is a return to the name: Bank of New York Mellon previously reported a position in KYTX as recently as Q1 2025.

Bank of New York Mellon first reported a position in KYTX in Q2 2024 and has held it in 5 quarters since. 59 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • Bank of New York Mellon held 100,281 shares of Kyverna Therapeutics worth $894K as of Q2 2026.
  • Kyverna Therapeutics was a new Bank of New York Mellon position in Q2 2026.
  • Kyverna Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3433 holding.
  • Bank of New York Mellon first reported a position in Kyverna Therapeutics in Q2 2024 and has held it in 5 quarters since.
  • 59 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.